Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Simple Summary Nowadays, the upfront treatment for patients facing a diagnosis of
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …

Abstract Cyclin-dependent kinase 7 (CDK7) serves as a pivotal regulator in orchestrating
cellular cycle dynamics and gene transcriptional activity. Elevated expression levels of …

Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical
challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase …

Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive
breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very …

Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-
dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in …

BACKGROUND Cyclin-dependent kinase (CDK) 7 is aberrantly overexpressed in many
types of cancer and is an attractive target for cancer therapy due to its dual role in …

Aims The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce
apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that …

Background Osteosarcoma (OS) is one of the most common primary malignant tumors of
bone in children, which develops from osteoblasts and typically occurs during the rapid …

Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype.
Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for …